Profile data is unavailable for this security.
About the company
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE).
- Revenue in USD (TTM)0.00
- Net income in USD-8.82m
- Incorporated2021
- Employees--
- LocationEstrella Immunopharma Inc5858 Horton Street, Suite 370EMERYVILLE 94608United StatesUSA
- Phone+1 (510) 318-9098
- Fax+1 (847) 827-5303
- Websitehttps://www.estrellabio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chemomab Therapeutics Ltd - ADR | 0.00 | -14.40m | 30.54m | 20.00 | -- | 1.91 | -- | -- | -0.9868 | -0.9868 | 0.00 | 0.8654 | 0.00 | -- | -- | 0.00 | -64.98 | -- | -83.24 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.39 | -- | -- | -- |
| RenovoRx Inc | 0.00 | -9.16m | 30.94m | 8.00 | -- | 4.38 | -- | -- | -0.572 | -0.572 | 0.00 | 0.2946 | 0.00 | -- | -- | 0.00 | -135.25 | -- | -180.14 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.47 | -- | -- | -- |
| Passage Bio Inc | 0.00 | -68.80m | 31.19m | 58.00 | -- | 0.429 | -- | -- | -1.17 | -1.17 | 0.00 | 1.18 | 0.00 | -- | -- | 0.00 | -48.97 | -48.56 | -56.34 | -52.09 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.02 | -- | -43.53 | -- |
| DURECT Corp | 8.59m | -17.07m | 31.35m | 45.00 | -- | 25.76 | -- | 3.65 | -0.5556 | -0.5556 | 0.2813 | 0.0392 | 0.2181 | 0.7417 | 9.05 | 148,172.40 | -43.33 | -37.34 | -156.35 | -53.44 | 78.87 | 91.83 | -198.62 | -139.11 | 0.5963 | -24.30 | 0.8958 | -- | -55.67 | -10.96 | 21.82 | -- | -10.98 | -- |
| Clene Inc. | 421.00k | -36.02m | 31.62m | 82.00 | -- | -- | -- | 75.10 | -5.58 | -5.58 | 0.0652 | -0.6016 | 0.0092 | 0.7759 | 13.16 | 5,134.15 | -78.31 | -39.43 | -136.18 | -47.32 | 78.62 | -- | -8,556.77 | -5,261.20 | 0.8213 | -10.15 | 1.30 | -- | 38.27 | -- | -65.47 | -- | -- | -- |
| LianBio - ADR | 0.00 | -87.98m | 32.15m | 163.00 | -- | 0.1576 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
| CERo Therapeutics Holdings Inc | 0.00 | -2.54m | 32.18m | 8.00 | -- | -- | -- | -- | -0.3796 | -0.3796 | 0.00 | -0.9226 | 0.00 | -- | -- | 0.00 | -9.96 | -- | -33.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -279.82 | -- | -- | -- |
| Hcw Biologics Inc | 3.50m | -37.33m | 32.33m | 45.00 | -- | -- | -- | 9.25 | -1.00 | -1.00 | 0.0939 | -0.2636 | 0.1125 | -- | 5.13 | 77,688.45 | -120.09 | -- | -279.71 | -- | 32.41 | -- | -1,067.83 | -- | -- | -93.78 | 4.52 | -- | -57.72 | -- | -67.74 | -- | -- | -- |
| Estrella Immunopharma Inc | 0.00 | -8.82m | 32.93m | -- | -- | 44.12 | -- | -- | -0.2378 | -0.2378 | 0.00 | 0.0206 | 0.00 | -- | -- | -- | -56.73 | -- | -163.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 34.21 | -- | -- | -- |
| Lantern Pharma Inc | 0.00 | -19.09m | 33.22m | 21.00 | -- | 1.25 | -- | -- | -1.77 | -1.77 | 0.00 | 2.47 | 0.00 | -- | -- | 0.00 | -48.91 | -28.83 | -52.88 | -30.17 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.93 | -- | -- | -- |
| Grace Therapeutics, Inc | 0.00 | -11.61m | 33.26m | 32.00 | -- | 0.5925 | -- | -- | -1.08 | -1.08 | 0.00 | 5.54 | 0.00 | -- | -- | -- | -16.17 | -31.68 | -16.64 | -33.95 | -- | -- | -- | -56,271.43 | -- | -- | 0.00 | -- | -- | -- | 69.71 | -- | -47.16 | -- |
| NextCure Inc | 0.00 | -58.52m | 33.33m | 82.00 | -- | 0.4404 | -- | -- | -2.09 | -2.09 | 0.00 | 2.70 | 0.00 | -- | -- | 0.00 | -50.82 | -22.59 | -54.42 | -23.54 | -- | -- | -- | -964.96 | -- | -- | 0.00 | -- | -- | -- | 16.07 | -- | -23.17 | -- |
| Curis Inc | 10.26m | -45.48m | 33.46m | 48.00 | -- | -- | -- | 3.26 | -7.81 | -7.81 | 1.76 | -1.45 | 0.1549 | -- | 3.52 | 213,729.20 | -68.68 | -37.25 | -94.06 | -41.12 | 98.68 | 96.05 | -443.35 | -409.44 | -- | -- | -- | -- | -1.37 | -0.7891 | 16.34 | -- | -- | -- |
| Promis Neurosciences Inc | 0.00 | -563.35k | 33.65m | 6.00 | -- | 4.63 | -- | -- | -0.1931 | -0.1931 | 0.00 | 0.2225 | 0.00 | -- | -- | 0.00 | -2.66 | -144.28 | -3.77 | -262.23 | -- | -- | -- | -2,271,047.00 | -- | -- | 0.00 | -- | -- | -- | 26.85 | -- | -- | -- |
| Carisma Therapeutics Inc | 20.27m | -63.80m | 34.34m | 107.00 | -- | -- | -- | 1.69 | -1.56 | -1.56 | 0.4927 | -0.2665 | 0.2723 | -- | -- | 189,420.60 | -85.73 | -30.87 | -101.81 | -34.47 | -- | -- | -314.78 | -255.66 | -- | -- | -- | -- | -62.70 | -- | -336.93 | -- | 255.27 | -- |
Data as of Nov 25 2024. Currency figures normalised to Estrella Immunopharma Inc's reporting currency: US Dollar USD
0.55%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Geode Capital Management LLCas of 30 Sep 2024 | 76.56k | 0.21% |
| ATW SPAC Management LLCas of 30 Sep 2024 | 40.00k | 0.11% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 22.59k | 0.06% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 21.68k | 0.06% |
| Citadel Securities LLCas of 30 Sep 2024 | 14.53k | 0.04% |
| Maso Capital Partners Ltd.as of 30 Sep 2024 | 10.00k | 0.03% |
| UBS Securities LLCas of 30 Sep 2024 | 6.52k | 0.02% |
| Tower Research Capital LLCas of 30 Sep 2024 | 5.73k | 0.02% |
| BlackRock Investment Management LLCas of 30 Sep 2024 | 2.37k | 0.01% |
| Bank of America, NA (Private Banking)as of 30 Sep 2024 | 83.00 | 0.00% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
